XNK Therapeutics AB today announced that the first patient has been treated in a Phase II clinical study using XNK’s leading autologous natural killer (NK) cell-based candidate drug in combination with Sanofi’s anti-CD38 antibody Sarclisa (Isatuximab). “Having the first patient treated with NK cells in this clinical study is an important milestone in the clinical…
ສິ່ງທີ່ຄວນເອົາໄປຈາກບົດຄວາມນີ້:
- “Having the first patient treated with NK cells in this clinical study is an important milestone in the clinical….
- XNK Therapeutics AB ປະກາດໃນມື້ນີ້ວ່າຄົນເຈັບຄົນທໍາອິດໄດ້ຮັບການປິ່ນປົວໃນການສຶກສາທາງດ້ານຄລີນິກໄລຍະ II ໂດຍໃຊ້ຢາຂ້າເຊື້ອທໍາມະຊາດຊັ້ນນໍາຂອງ XNK ຂອງ autologous natural killer (NK) ປະສົມປະສານກັບ Sanofi's anti-CD38 antibody Sarclisa (Isatuximab).
- ເນື້ອໃນນີ້ແມ່ນສໍາລັບສະມາຊິກສະຫມັກຟຣີເທົ່ານັ້ນ.